|
|
Volumn 22, Issue 12, 1999, Pages 535-540
|
|
Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT;
4 PHOSPHONOMETHYLPIPECOLIC ACID;
ALTEPLASE;
ANTIINFLAMMATORY AGENT;
APTIGANEL;
CALCIUM CHANNEL BLOCKING AGENT;
CITICOLINE;
CLOMETHIAZOLE;
DIZOCILPINE;
EBSELEN;
ELIPRODIL;
ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1;
FLUNARIZINE;
FOSPHENYTOIN SODIUM;
GANGLIOSIDE GM1;
GAVESTINEL;
INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY;
LUBELUZOLE;
MAGNESIUM SULFATE;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;
NIMODIPINE;
NITRIC OXIDE SYNTHASE INHIBITOR;
PHENYTOIN;
PIRACETAM;
SCAVENGER;
SODIUM CHANNEL BLOCKING AGENT;
TIRILAZAD;
TROFERMIN;
UNCLASSIFIED DRUG;
BRAIN ISCHEMIA;
BRAIN PROTECTION;
CATATONIA;
CLINICAL TRIAL;
DISABILITY;
DROWSINESS;
DRUG MECHANISM;
DRUG SAFETY;
HUMAN;
NERVE CELL NECROSIS;
NEUROTOXICITY;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PATIENT SELECTION;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
REVIEW;
STROKE;
BRAIN ISCHEMIA;
CEREBROVASCULAR ACCIDENT;
CLINICAL TRIALS;
EVALUATION STUDIES;
HUMANS;
NEUROPROTECTIVE AGENTS;
|
|
EID: 0033485704
PISSN: 01662236
EISSN: None
Source Type: Journal
DOI: 10.1016/S0166-2236(99)01463-0 Document Type: Review |
|
Times cited : (360)
|
|
References (8)
|
